50% offfirst month · every plan
Adult athlete pausing after a hard track session behind rain-streaked glass.
TB-500

Recovery that keeps pace

When soreness is gone, but the setback is still there.

TB-500 draws recovery interest from studies of actin, cell movement, collagen, and wound closure—the cellular work involved when tissue responds to injury.

For Rebody members.

Join Rebody

Free account.

View TB-500

Why actin matters

Recovery depends on cells being able to move.

Actin helps cells hold shape, create force, and migrate through changing tissue. TB-500 commonly refers to a seven-amino-acid region containing thymosin beta-4’s actin-binding segment.

Recovery lag feels specific

The workout ended. The workaround did not.

It is the shortened stride, the cautious first set, or the movement you quietly avoid. Those moments make studies of actin, cell movement, collagen, and wound closure feel personal.

Recovery lagThe distance between wanting to move and trusting the load.
Adult man with a towel pauses in hard sunlight after training.
Translucent G-actin, peptide fragment, and F-actin filament illustrate the actin assembly sequence.

The actin connection

7 aa

A short sequence inside the machinery of cell movement.

LKKTETQ contains the six-amino-acid LKKTET region known for actin binding. G-actin units assemble into F-actin filaments as cells change shape and move.

Explore the molecular evidence →
Translucent aged laboratory mouse beside dorsal-skin specimens illustrating closure and collagen measurements.

Aged-mouse wound study

More epidermal closure and collagen at day seven.

Investigators applied 0.01% non-acetylated LKKTETQ topically to dorsal punch wounds in 26-month-old female mice on day zero and at 48 hours. Day-seven histology measured greater epidermal closure and collagen content.

26 mofemale mice
0.01%topical LKKTETQ
Day 7histology
Read the original study ↗
Illustrative clear TB-500 10 mg injection vial with a silver cap and white label.Illustrative packaging

Planned TB-500 injection

Know which TB-500 is in the vial.

Free base and acetate are distinct substances. The product guide keeps the exact formulation, directions, supply, storage, pharmacy, and price together.

Planned format
Injection vial
Planned amount
10 mg
Pharmacy
Licensed U.S. compounding pharmacy
Product details
Exact substance, directions, storage, supply, and price
See TB-500 product details

Direct TB-500 assay

TB-500 and vehicle were statistically similar.

In an eight-hour fibroblast scratch assay, 50 µg/mL TB-500 produced no significant difference in wound closure versus vehicle. The N-acetylated LKKTE metabolite produced a small significant change.

Read the evidence review ↗

Read TB-500 in the right order

Identity before mechanism. Results before hype.

Three short chapters keep the seven-amino-acid fragment separate from the much larger story around thymosin beta-4.

TB-500 product details

Exact substance, price, supply, and pharmacy.

Study notes, product details, and sources in one Rebody account.

  1. 01

    TB-500 evidence

    Actin-fragment, cell-migration, and wound-model studies.

  2. 02

    Product details

    Exact substance, price, supply, pharmacy, and injection routine.

  3. 03

    Decide from the label

    Directions, storage, and beyond-use date will match the finished formulation.

TB-500

More on TB-500.

Keep the evidence, product details, and practical questions in one Rebody account.

Planned amount
10 mg
Planned format
Injection vial
Evidence
Seven-amino-acid fragment

More on TB-500.

TB-500 evidence and product details in one Rebody account.

Join Rebody

Free account.

TB-500 questions

Questions about TB-500.

What is included in the TB-500 guide?

Study notes, product details, sources, and the practical questions around substance, formulation, supply, storage, and price.

Why is TB-500 discussed for recovery?

TB-500 commonly refers to a seven-amino-acid fragment containing thymosin beta-4’s actin-binding region. Actin dynamics sit underneath cell shape and movement, while related laboratory and animal work has measured migration, blood-vessel formation, wound closure, and collagen.

What have direct TB-500 studies found?

In one eight-hour fibroblast scratch assay, 50 µg/mL TB-500 produced no significant difference in wound closure versus vehicle. The N-acetylated LKKTE metabolite produced a small significant change under the same conditions.

How would Rebody offer TB-500?

The planned format is a 10 mg injection vial filled by a licensed U.S. compounding pharmacy. The product guide covers substance, concentration, directions, price, supply, and storage.